Dr. Reddy’s: Lessons from Omeprazole - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Dr. Reddy’s: Lessons from Omeprazole

Nov 20, 2001

Yesterday, Dr. Reddy’s ADR was down by around 18% on the NYSE following withdrawal of tentative Omeprazole approval which seems to have worked as a major anti-climax for investors. Whether the fall was justified or the market overreacted to the news is a different story but the point here is investors need to understand the nature of generic business before investing. Apart from the company’s capability, what matters is the timing, patience, skills and financial muscle to fight legal battles. This is all the more true in case of Para IV applications. A Para IV application is one in which a generic company challenges a patented product to prove that the generic version can stand the same test of efficacy. Further, to get six months marketing exclusivity the company also needs to be the first to file this application.

Now, the cream for the original innovator of the drug is the period the drug remains under patent, as it charges a hefty premium for it innovation and monopoly. Off course, the innovator would try to prevent the entry of a generic product and to do so various legal provisions; loopholes and financial muscle are used as war tactics. It is after all this legal drama that the generic drug enters a regulated market. Now, one can understand the degree of uncertainty, which precedes and follows launch of a generic product.

Let us consider a recent Bristol Myers, BuSpar case to understand the complexities. BuSpar is Bristol Myers multi-million anti-anxiety drug. After its patent expiry, a lower court in the US gave the green signal for entry of two generic copycats (from Watson and Mylan). However, months after the lower court gave this decision, US Court of Appeals reversed the earlier decision stating the lower court had no power to order US FDA to overlook the patent and pave the way for generics.

To conclude, there is a big opportunity waiting for Indian generic companies who are geared to latch on to that market. However, the road ahead would not be smooth and there would be negative surprises along the way. It would be advisable for investors in domestic pharma companies not to build expectations and factor in growth numbers either from generics or from R&D potential till clear earnings visibility arises on that front.

  • Read on the latest Omeprazole development

  • Equitymaster requests your view! Post a comment on "Dr. Reddy’s: Lessons from Omeprazole". Click here!


    More Views on News

    Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

    May 24, 2021

    With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

    Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

    May 14, 2021

    The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

    5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

    Sep 3, 2021

    These companies are likely to benefit the most from Covid-19 vaccines.

    5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

    Dec 3, 2021

    As the new variant of Covid-19 emerges, keep an eye on these stocks.

    This Stock Just Made a Historical Debut on the Exchanges (Views On News)

    Nov 15, 2021

    Shares of the company listed at premium of 253% from its IPO price, the highest ever.

    More Views on News

    Most Popular

    Infosys vs TCS: Which is Better? (Views On News)

    Nov 26, 2021

    In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

    This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

    Nov 24, 2021

    Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

    6 Popular Stocks that Turned into Penny Stocks (Views On News)

    Nov 27, 2021

    A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

    India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

    Nov 30, 2021

    These 5 companies dominate their sectors with a huge piece of the pie.

    The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

    Nov 26, 2021

    How India's EV transition could be a major headwind for the incumbents.


    Become A Smarter Investor
    In Just 5 Minutes

    Multibagger Stock Guide 2022
    Get our special report Multibagger Stocks Guide (2022 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Dec 7, 2021 03:12 PM


    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks